Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a randomized, observer-blinded, placebo-controlled study to evaluate safety, tolerability, immunogenicity, and pharmacokinetics of repeat dosing of intravenous (IV) UTTR1147A. The study will consist of a repeat dose escalation in HVs, in participants with UC, and in participants with CD across multiple sites.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
General inclusion criteria:
For HVs Only:
For Participants with UC or CD:
Exclusion criteria
General exclusion criteria:
For HVs Only:
For Participants with UC or CD:
Primary purpose
Allocation
Interventional model
Masking
70 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal